Randomized Phase III Trial of Gemcitabine Plus Docetaxel Plus Bevacizumab or Placebo As First-Line Treatment for Metastatic Uterine Leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group Study

PURPOSE: Fixed-dose rate gemcitabine plus docetaxel achieves objective response in 35% of patients with uterine leiomyosarcoma (uLMS). This study aimed to determine whether the addition of bevacizumab to gemcitabine-docetaxel increases progression-free survival (PFS) in uLMS. PATIENTS AND METHODS: I...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Oncol
Hlavní autoři: Hensley, Martee L., Miller, Austin, O'Malley, David M., Mannel, Robert S., Behbakht, Kian, Bakkum-Gamez, Jamie N., Michael, Helen
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2015
Témata:
ORIGINAL REPORTS
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4372854/
https://ncbi.nlm.nih.gov/pubmed/25713428
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.58.3781
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky